The deal follows a $1.06 billion U.S. contract in July 2024 and a $1.24 billion agreement with an Asia-based pharma a few ...

Samsung Biologics, the country’s leading pharmaceutical contract manufacturing organization (CMO), announced Tuesday it has secured its largest-ever deal, valued at over 2 trillion won ($1.4 billion).

Samsung Biologics has signed a contract worth 111.2 billion won ($77 million) with an undisclosed U.S. pharmaceutical firm to provide contract manufacturing organization (CMO) services.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Teva Pharmaceutical Industries Ltd. and Samsung Bioepis Co., Ltd. announced that they entered into a licensing ...

Marks a significant advancement in offering new treatment options for patients with rare diseases like paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and ...

Samsung Bioepis and Teva have entered into a license, development and commercialization agreement for Epysqli ...

New partnerships aim to expand Teva’s biosimilar portfolio and enhance access to high-cost biologics across key markets.